Reviewed by Michael Gill, B. Sc.
Image of Canadian Center for Vaccinology in Halifax, Canada.
Phase-Based Progress Estimates

Group G3, Subgroup G3-Afor COVID-19

18 - 65
All Sexes
VBI-2901e is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and MERS-CoV. The trivalent vaccine candidate is designed to induce neutralizing antibody and cell-mediated immune responses against the spike protein of the original strain of SARS-CoV-2 coronavirus, variants and subvariants of SARS-CoV-2 (such as Beta, Delta and Omicron BA.5) and other related coronaviruses that could emerge in the future. VBI-2901e contains two adjuvants: aluminum phosphate and E6020. The role of the adjuvants is to create a stronger immune response to the vaccine. This Phase 1 study will be an open-label study of VBI-2901e comparing three dose levels of the E6020 adjuvant component (1, 3, or 10 µg per dose) in adults 18 to 40 years of age who had previously received two or more vaccinations with licensed COVID-19 vaccine(s). VBI-2901e at each dose level of E6020 will be administered as either a single dose or two-dose regimen. The purpose of the study is to test the safety of VBI-2901e and to learn more about its ability to boost immune responses against SARS-CoV-2 and the two related coronaviruses SARS-CoV-1 and MERS-CoV.
Phase 1
Waitlist Available
Canadian Center for Vaccinology (+3 Sites)William Cameron, MDVBI Vaccines Inc.
25 Vaccine Clinical Trials Near Me
Top Hospitals for Vaccine Clinical Trials
Image of Coastal Carolina Research Center in South Carolina.
Coastal Carolina Research Center
North Charleston
6Active Trials
0All Time Trials for Vaccine
2021First Vaccine Trial
Image of GSK Investigational Site in Texas.
GSK Investigational Site
San Antonio
6Active Trials
0All Time Trials for Vaccine
2016First Vaccine Trial
Top Cities for Vaccine Clinical Trials
Image of Houston in Texas.
37Active Trials
Texas Center for Drug Development, Inc.Top Active Site
Vaccine Clinical Trials by Phase of Trial
Phase < 1 Vaccine Clinical Trials
8Active Vaccine Clinical Trials
8Number of Unique Treatments
9Number of Active Locations
TrametinibPneumococcal 13-valent Conjugate VaccineMalignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell VaccineNeoadjuvant ChemotherapyMulti-epitope Folate Receptor Alpha-loaded Dendritic Cell VaccineAnifrolumabSingle Influenza VaccineDKK1
Vaccine Clinical Trials by Age Group
< 18 Vaccine Clinical Trials
13Active Vaccine Clinical Trials
9vHPV VaccineRSV vaccine formulation 2Experimental: PIVOT with MIMenACYW conjugate vaccineHepatitis B VaccineFluadTrivalent Influenza VaccineRSV LID/ΔM2-2/1030s